FDA grants GSK accelerated approval for ALK inhibitor Nelkarmi
FDA granted GSK accelerated approval for Nelkarmi (neladalkib) in pre-treated ALK-positive NSCLC, with a 49% ORR after one prior ALK inhibitor and activity against brain metastases.
TAG C-7994 · 333 words on the filing

Summary of findings
- FDA granted accelerated approval to Nelkarmi (neladalkib) ahead of its original decision deadline
- 49% confirmed ORR in patients with one prior ALK inhibitor; 32% after two or more plus chemotherapy (ALKOVE-1 Phase I/II)
- GSK's second lung cancer approval of the year
- Drug holds FDA Breakthrough Therapy and Orphan Drug designations; filings underway in other markets
- GSK shares down 0.08% at 1,867.50p as of 1010 GMT
The US Food and Drug Administration granted accelerated approval to Nelkarmi (neladalkib) ahead of its original decision deadline, clearing the drug for previously treated patients with advanced ALK-positive non-small cell lung cancer. The nod marks GSK's second lung cancer approval of the year and lands well before the regulator's planned date.
The filing rests on data from the ALKOVE-1 Phase I/II trial, which showed clinically meaningful and durable responses in patients who had already received ALK inhibitor therapies. GSK framed the next-generation molecule as designed for three specific problems: treatment resistance, tolerability, and disease that has spread to the brain.
How strong are the numbers?
Among patients treated with only one prior ALK inhibitor, Nelkarmi delivered a confirmed overall response rate of 49%. Patients who had received two or more prior ALK inhibitors plus chemotherapy achieved a response rate of 32%.
Both figures come from early-phase data, not a randomized pivotal trial, and accelerated approval carries a confirmation obligation. GSK's statement did not specify the timeline or design of any confirmatory study.
What about brain metastases?
The therapy demonstrated encouraging activity against brain metastases, which the company called a key challenge in ALK-positive lung cancer. GSK did not publish intracranial response figures in the announcement, leaving that claim on characterization rather than numbers.
The drug previously received FDA Breakthrough Therapy and Orphan Drug designations, and GSK said the approval strengthens its growing oncology portfolio.
What happens next?
Regulatory filings are being pursued in other markets, though GSK did not name jurisdictions or expected decision dates. The company also highlighted that Nelkarmi's differentiated profile could address unmet needs in patients whose disease has progressed on existing treatments — a population where options narrow quickly after second-line failure.
The market reaction was muted. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p, suggesting investors had largely priced in the early decision or are waiting on confirmatory and commercial data.
via FDA industry wire (Google News) (Source)
More from Rebecca Stone
Show full bio
Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
10 articles
Linked filings
- C-6506
- V-1848
- C-9698
- K-5457
- P-9899